OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SOUTH SAN FRANCISCO, Calif., May 03, 2017 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s first quarter 2017 financial results will be released on Tuesday, May 9, 2017. Company management will host a conference call on Tuesday, May 9, 2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 18046993. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in collaboration with Incyte Corporation and is currently in a Phase 1 clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT: Jennifer McNealey [email protected] 650-870-1071
